Phosphate-mediated coanchoring of RBD immunogens and molecular adjuvants to alum potentiates humoral immunity against SARS-CoV-2

Coanchoring a SARS-CoV-2 immunogen and molecular adjuvants to alum extends vaccine kinetics and amplifies humoral immunity.

[1]  D. Irvine,et al.  A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity , 2021, Science Immunology.

[2]  B. Pulendran,et al.  Adjuvanting a subunit COVID-19 vaccine to induce protective immunity , 2021, Nature.

[3]  D. Sheward,et al.  SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses , 2021, Cell Reports Medicine.

[4]  Jessica E. Rothman,et al.  Early introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United States , 2021, Cell.

[5]  Laura E. Crowell,et al.  Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters , 2021, bioRxiv.

[6]  D. Fremont,et al.  Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies , 2021, Nature Medicine.

[7]  B. Haynes,et al.  Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates , 2021, bioRxiv.

[8]  H. Mouquet,et al.  Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies , 2021, Nature Medicine.

[9]  Vineet D. Menachery,et al.  Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant , 2021, medRxiv.

[10]  Jing-xin Li,et al.  Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need , 2021, Signal Transduction and Targeted Therapy.

[11]  Charles Y. Tan,et al.  BNT162b vaccines protect rhesus macaques from SARS-CoV-2 , 2021, Nature.

[12]  P. Dormitzer,et al.  Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera , 2021, Science.

[13]  M. V. van Breemen,et al.  Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection , 2020, Cell.

[14]  D. Lauffenburger,et al.  Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.

[15]  Sergei L. Kosakovsky Pond,et al.  Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa , 2020, medRxiv.

[16]  D. Lauffenburger,et al.  Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.

[17]  Xin He,et al.  Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses , 2020, Immunity.

[18]  F. Krammer.  SARS-CoV-2 vaccines in development , 2020, Nature.

[19]  J. Greenbaum,et al.  Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity , 2020, Cell.

[20]  N. Patel,et al.  NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge , 2020, bioRxiv.

[21]  R. Coffman,et al.  Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19 , 2020, Scientific Reports.

[22]  S. Mallal,et al.  Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans , 2020, Science.

[23]  Yuquan Wei,et al.  A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity , 2020, Nature.

[24]  D. Weissman,et al.  D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization , 2020, Cell Host & Microbe.

[25]  Lisa E. Gralinski,et al.  Potently neutralizing and protective human antibodies against SARS-CoV-2 , 2020, Nature.

[26]  G. Gao,et al.  A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS , 2020, Cell.

[27]  D. Burton,et al.  Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.

[28]  C. Rice,et al.  Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.

[29]  I. Wilson,et al.  A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV , 2020, Science.

[30]  Yan Liu,et al.  Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV , 2020, Nature Communications.

[31]  Shibo Jiang,et al.  Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine , 2020, Cellular & Molecular Immunology.

[32]  Daniel W. Kulp,et al.  Engineered immunogen binding to alum adjuvant enhances humoral immunity , 2020, Nature Medicine.

[33]  Daniel W. Kulp,et al.  Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance , 2018, Cell.

[34]  Yu Wang,et al.  On-demand manufacturing of clinical-quality biopharmaceuticals , 2018, Nature Biotechnology.

[35]  Xun Sun,et al.  Turning the Old Adjuvant from Gel to Nanoparticles to Amplify CD8+ T Cell Responses , 2017, Advanced science.

[36]  Daniel E. Zak,et al.  Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs. , 2017, Blood advances.

[37]  Daniel W. Kulp,et al.  Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches , 2017, Immunity.

[38]  Daniel G. Anderson,et al.  Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination , 2016, Proceedings of the National Academy of Sciences.

[39]  Fangjia Lu,et al.  Control of antigen-binding to aluminum adjuvants and the immune response with a novel phosphonate linker. , 2013, Vaccine.

[40]  L. Babiuk,et al.  Combination adjuvants: the next generation of adjuvants? , 2011, Expert review of vaccines.

[41]  T. Kündig,et al.  Antigen kinetics determines immune reactivity , 2008, Proceedings of the National Academy of Sciences.

[42]  S. Hem,et al.  Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation , 2007, Expert review of vaccines.

[43]  Anna Sokolovska,et al.  Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response. , 2007, Vaccine.

[44]  Gary J. Nabel,et al.  A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice , 2004, Nature.

[45]  C. Johnston,et al.  Measuring the surface area of aluminum hydroxide adjuvant. , 2002, Journal of pharmaceutical sciences.

[46]  A. Sette,et al.  Linear PADRE T Helper Epitope and Carbohydrate B Cell Epitope Conjugates Induce Specific High Titer IgG Antibody Responses1 , 2000, The Journal of Immunology.

[47]  C. Siegrist,et al.  CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.